Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.

Journal of hepatology - 1 Sept 2011

Seto Wai-Kay, Lai Ching-Lung, Fung James, Wong Danny Ka-Ho, Yuen John Chi-Hang, Hung Ivan Fan-Ngai, Yuen Man-Fung

Abstract excerpt

BACKGROUND & AIMS: The significance of early HBV DNA suppression during telbivudine treatment in predicting long-term outcomes needs further investigation. METHODS: We determined the cumulative rates of HBeAg seroconversion, ALT normalization, HBV DNA suppression (<12IU/ml) and telbivudine resistant mutations (using the highly sensitive line probe assay) for 117 treatment-native chronic hepatitis B (CHB) patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Nucleosides

Share to Pyrimidinones

Share to Thymidine

Share to Viral Load

Source

Identifiers

PMID: 21147187
DOI: 10.1016/j.jhep.2010.11.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.PMID 21147187Read ↗

The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.Semantic proximity Read ↗

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.Semantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.Semantic proximity Read ↗

Telbivudine versus lamivudine in patients with chronic hepatitis B.Semantic proximity Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

Dynamics of HBV DNA levels, HBV mutations and biochemical parameters during antiviral therapy in a patient with HBeAg-negative chronic hepatitis B.Semantic proximity Read ↗

Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment.Semantic proximity Read ↗

Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.Semantic proximity Read ↗

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.Semantic proximity Read ↗

Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment.Semantic proximity Read ↗

Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.